“Primary Hyperoxyaluria Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Hyperoxyaluria Market.

The Primary Hyperoxyaluria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Primary Hyperoxyaluria Pipeline Report:

• Companies across the globe are diligently working toward developing novel Primary Hyperoxyaluria treatment therapies with a considerable amount of success over the years. 

• Primary Hyperoxyaluria companies working in the treatment market are Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, Biocodex, and others, are developing therapies for the Primary Hyperoxyaluria treatment 

• Emerging Primary Hyperoxyaluria therapies in the different phases of clinical trials are- Lumasiran, nedosiran, Stiripentol, DCR-PHXC, and others are expected to have a significant impact on the Primary Hyperoxyaluria market in the coming years.   

• In October 2023, Novo Nordisk has obtained approval from the US Food and Drug Administration (FDA) for Rivfloza (nedosiran) injection, aimed at lowering urinary oxalate levels in children aged nine and above, and adults with primary hyperoxaluria type 1 (PH1) who have relatively preserved kidney function. PH1 is a rare genetic disorder that leads to oxalate overproduction by the liver, affecting approximately one in 38,600 individuals worldwide. The approved doses of Rivfloza are 80mg, 128mg, or 160mg, administered monthly as a subcutaneous ribonucleic acid interference therapy. This approval is based on data from the pivotal Phase II PHYOX2 clinical study and interim results from the ongoing Phase III PHYOX3 extension study.

• In October 2023, The Food and Drug Administration (FDA) has approved Rivfloza™ (nedosiran) to reduce urinary oxalate levels in children aged nine and older, as well as adults with primary hyperoxaluria type 1 (PH1) who have relatively preserved kidney function (e.g., estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m²).

Primary Hyperoxyaluria Overview

Primary hyperoxaluria (PH) is a rare genetic disorder characterized by the overproduction of oxalate, a substance that combines with calcium to form kidney stones and crystals, which can lead to kidney damage and other systemic complications. This condition is caused by deficiencies in specific liver enzymes involved in glyoxylate metabolism, leading to excess oxalate production.

Get a Free Sample PDF Report to know more about Primary Hyperoxyaluria Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/primary-hyperoxaluria-pipeline-insight

Emerging Primary Hyperoxyaluria Drugs Under Different Phases of Clinical Development Include:

• Lumasiran: Alnylam Pharmaceuticals

• nedosiran: Dicerna Pharmaceuticals

• Stiripentol: Biocodex

• DCR-PHXC: Dicerna Pharmaceuticals

Primary Hyperoxyaluria Route of Administration

Primary Hyperoxyaluria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Primary Hyperoxyaluria Molecule Type

Primary Hyperoxyaluria Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Primary Hyperoxyaluria Pipeline Therapeutics Assessment

• Primary Hyperoxyaluria Assessment by Product Type

• Primary Hyperoxyaluria By Stage and Product Type

• Primary Hyperoxyaluria Assessment by Route of Administration

• Primary Hyperoxyaluria By Stage and Route of Administration

• Primary Hyperoxyaluria Assessment by Molecule Type

• Primary Hyperoxyaluria by Stage and Molecule Type

DelveInsight’s Primary Hyperoxyaluria Report covers around 6+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Primary Hyperoxyaluria product details are provided in the report. Download the Primary Hyperoxyaluria pipeline report to learn more about the emerging Primary Hyperoxyaluria therapies

Some of the key companies in the Primary Hyperoxyaluria Therapeutics Market include:

Key companies developing therapies for Primary Hyperoxyaluria are – Dicerna Pharmaceuticals, Allena Pharmaceuticals, Genentech, Biocode, Alnylum Pharm, OxThera, Tecoland Corporation, Zhejiang Tianxin Pharmaceutical Co., Takeda Pharmaceuticals, Wuxi Further Pharmaceutical Co Ltd, and others.

Primary Hyperoxyaluria Pipeline Analysis:

The Primary Hyperoxyaluria pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Primary Hyperoxyaluria with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Hyperoxyaluria Treatment.

• Primary Hyperoxyaluria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Primary Hyperoxyaluria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Hyperoxyaluria market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Primary Hyperoxyaluria drugs and therapies

Primary Hyperoxyaluria Pipeline Market Drivers

• Genetic Advancements, Innovative Treatments, Increased Diagnosis Rates, Orphan Drug Designation, Rising Awareness, are some of the important factors that are fueling the Primary Hyperoxyaluria Market.

Primary Hyperoxyaluria Pipeline Market Barriers

• However, High Development Costs, Regulatory Challenges, Limited Patient Population, Clinical Trial Difficulties, Uncertain Long-term Efficacy, and other factors are creating obstacles in the Primary Hyperoxyaluria Market growth.

Scope of Primary Hyperoxyaluria Pipeline Drug Insight    

• Coverage: Global

• Key Primary Hyperoxyaluria Companies: Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, Biocodex, and others

• Key Primary Hyperoxyaluria Therapies: Lumasiran, nedosiran, Stiripentol, DCR-PHXC, and others

• Primary Hyperoxyaluria Therapeutic Assessment: Primary Hyperoxyaluria current marketed and Primary Hyperoxyaluria emerging therapies

• Primary Hyperoxyaluria Market Dynamics: Primary Hyperoxyaluria market drivers and Primary Hyperoxyaluria market barriers 

Request for Sample PDF Report for Primary Hyperoxyaluria Pipeline Assessment and clinical trials

Table of Contents

1. Primary Hyperoxyaluria Report Introduction

2. Primary Hyperoxyaluria Executive Summary

3. Primary Hyperoxyaluria Overview

4. Primary Hyperoxyaluria- Analytical Perspective In-depth Commercial Assessment

5. Primary Hyperoxyaluria Pipeline Therapeutics

6. Primary Hyperoxyaluria Late Stage Products (Phase II/III)

7. Primary Hyperoxyaluria Mid Stage Products (Phase II)

8. Primary Hyperoxyaluria Early Stage Products (Phase I)

9. Primary Hyperoxyaluria Preclinical Stage Products

10. Primary Hyperoxyaluria Therapeutics Assessment

11. Primary Hyperoxyaluria Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Primary Hyperoxyaluria Key Companies

14. Primary Hyperoxyaluria Key Products

15. Primary Hyperoxyaluria Unmet Needs

16 . Primary Hyperoxyaluria Market Drivers and Barriers

17. Primary Hyperoxyaluria Future Perspectives and Conclusion

18. Primary Hyperoxyaluria Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services